1. Clinical Overview
Recombinant Human Epidermal Growth Factor (rhEGF) is a topical biological agent that mimics the endogenous EGF, a 53-amino acid polypeptide. It is a potent mitogen for epithelial cells, fibroblasts, and keratinocytes, playing a crucial role in wound healing by stimulating cell proliferation, migration, and differentiation. In the Indian market, it is primarily formulated as a gel or cream for topical application in wound management.
| Onset | Duration | Bioavailability |
|---|---|---|
| Cellular effects begin within hours; visible clinical improvement in wound granulation is typically observed within 3-7 days of regular application. | Local effects at the wound site are sustained for 12-24 hours post-application, necessitating once or twice-daily dosing. | Negligible systemic bioavailability (<1%) when applied topically to intact or broken skin, as it acts locally and is a large polypeptide. |
2. Mechanism of Action
rhEGF is a ligand for the Epidermal Growth Factor Receptor (EGFR), a transmembrane tyrosine kinase receptor. Binding induces receptor dimerization and autophosphorylation, activating major intracellular signaling cascades (RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways). This leads to increased DNA synthesis, transcription of genes involved in cell cycle progression, and synthesis of proteins and extracellular matrix components essential for tissue repair.
3. Indications & Uses
- Diabetic Foot Ulcers (Grade 1 & 2 as per Wagner's classification)
- Venous Stasis Ulcers
- Pressure Sores (Stage II & III)
- Burn Wounds (partial thickness, after acute phase)
- Traumatic Skin Injuries and Abrasions
4. Dosage & Administration
Adult Dosage: Apply a thin layer (approx. 0.5 gm of gel per 10 sq cm wound area) once or twice daily, or as directed by the physician. The wound should be cleaned and debrided before each application.
Administration: 1. Cleanse wound thoroughly with normal saline or prescribed antiseptic. 2. Pat dry gently. 3. Apply a uniform thin layer to cover entire wound bed. 4. Cover with a sterile non-adherent dressing. 5. Wash hands before and after application. Do not use occlusive dressings unless advised.
5. Side Effects
Common side effects may include:
- Transient mild burning or stinging at application site
- Localized erythema (redness)
- Itching (pruritus)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Topical Corticosteroids (e.g., Betamethasone, Clobetasol) | May antagonize the wound healing and proliferative effects of rhEGF. | Moderate |
| Topical Antiseptics (e.g., Povidone-Iodine, Hydrogen Peroxide) | Concurrent application may inactivate the protein. A time gap of at least 30 minutes between antiseptic wash and rhEGF application is recommended. | Significant |
| Other Topical Growth Factors or Biologicals | No data. Potential for additive effect or interference. Not recommended. | Unknown |
| Systematic Chemotherapeutic Agents (EGFR inhibitors like Cetuximab) | Theoretical antagonism at receptor level. Clinical significance for topical EGF is unknown. | Theoretical |
7. Patient Counselling
- DO clean the wound as instructed before every application.
- DO use a clean applicator or glove to apply the gel.
- DO keep the medicine refrigerated (2-8°C). The tube in use can be kept at room temperature (below 25°C) for up to 30 days.
- DON'T apply the gel to infected wounds without concurrent antibiotic therapy.
- DON'T use occlusive dressings unless specifically told by your doctor.
- DON'T stop using the medicine even if healing seems rapid; complete the prescribed course.
8. Toxicology & Storage
Overdose: Topical overdose is unlikely to cause systemic symptoms. Excessive local application may lead to increased frequency of local side effects like burning, pain, and hypergranulation tissue.
Storage: Store unopened tubes in a refrigerator between 2°C and 8°C. Do not freeze. Protect from light. Once opened, the tube can be kept at room temperature (not exceeding 25°C) for a period of up to 30 days. Keep out of reach of children. Do not use after the expiry date.